The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts Myocardial injury following elective percutaneous coronary intervention

Clinical Cardiology

Volumn 37, Issue 9, 2014, Pages 558-565

  Li, Xiao N ^a   Li, Jian Jun ^a   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Qing, Ping ^a   Wu, Na Qiong ^a   Xu, Bo ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CARDIAC TROPONIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN I; UNCLASSIFIED DRUG; APOA1 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CARDIAC TROPONIN 1 CLIA KIT; DIABETES MELLITUS; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PROSPECTIVE STUDY; ADVERSE EFFECTS; AGED; BLOOD; CHINA; CORONARY ARTERY DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL REPERFUSION INJURY; PROTECTION; RISK; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CHINA; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL REPERFUSION INJURY; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 84908306165     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22308     Document Type: Article

References (40)

1. Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, et al.Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
2. Miller M, Mead LA, Kwiterovich PO Jr, et al. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol. 1990;65:1-5.
3. Miller M, Seidler A, Kwiterovich PO, et al. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation.1992;86:1165-1170.
4. Mehra MR, Uber PA, Lavie CJ, et al. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant. 2009;28:876-880.
5. Freitas HF, Barbosa EA, Rosa FH, et al. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res. 2009;42:420-425.
6. Den Ruijter HM, Franssen R, Verkerk AO, et al. Reconstituted high-density lipoprotein shortens cardiac repolarization. J Am CollCardiol. 2011;58:40-44.
7. Rye KA, Barter PJ. Cardioprotective functions of HDLs. J LipidRes. 2014;55:168-179.
8. Prasad A. Slow but steady progress towards understanding periprocedural myocardial infarction. Eur Heart J. 2013;34:1615-1617.
9. Nienhuis MB, Ottervanger JP, Bilo HJ, et al. Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv. 2008;71:318-324.
10. Sattler KJ, Herrmann J, Yun S, et al. High high-density lipoprotein cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J. 2009;30:1894-1902.
11. Martin SS, Qasim AN, WolfeM, et al. Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. Am J Cardiol. 2011;107:393-398.
12. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation.2001;103:2780-2783.
13. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation.2005;111:1027-1032.
14. Lee T, Yonetsu T, Koura K, et al. Impact of coronary plaque morphology assessed by optical coherence tomography on cardiac troponin elevation in patients with elective stent implantation. Circ Cardiovasc Interv. 2011;4:378-386.
15. Goldstein JA, Maini B, Dixon SR, et al. Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction. Circ Cardiovasc Interv. 2011;4:429-437.
16. Besler C, Luscher TF, Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4:251-268.
17. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res. 2013;54:3227-3243.
18. Zaratin AC, Quintao EC, Sposito AC, et al. Smoking prevents the intravascular remodeling of high-density lipoprotein particles: implications for reverse cholesterol transport. Metabolism. 2004;53:858-862.
19. GowriMS, Van der Westhuyzen DR, Bridges SR, et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol. 1999;19:2226-2233.
20. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
21. de la Llera Moya M, McGillicuddy FC, Hinkle CC, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 2012;222:390-394.
22. Frikke-Schmidt R, Nordestgaard BG, SteneMC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524-2532.
23. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
24. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-642.
25. Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med. 2006;259:447-454.
26. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.N Engl J Med. 1991;325:373-381.
27. Meisinger C, Loewel H, Mraz W, et al. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26:271-278.
28. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I andB levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-278.
29. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
30. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49-55.
31. Miwa K, Yoshida N, Nakagawa K, et al. High-density lipoprotein particles are large in patients with variant angina. Cardiovasc Res. 1998;37:729-737.
32. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
33. Sung KC, Wild SH, Byrne CD. Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. Atherosclerosis. 2013;231:181-186.
34. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation. 2000;102:2197-2203.
35. Miller NE, Rajput-Williams J, Nanjee MN, et al. Relationship of high density lipoprotein composition to plasma lecithin: cholesterol acyltransferase concentration in men. Atherosclerosis. 1988;69:123-129.
36. Mazer NA, Giulianini F, Paynter NP, et al. A comparison of the theoretical relationship between HDL size and the ratio of HDLcholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem. 2013;59:949-958.
37. Shen BW, Scanu AM, Kezdy FJ. Structure of human serum lipoproteins inferred from compositional analysis. Proc Natl AcadSci U S A. 1977;74:837-841.
38. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 1999;145:227-238.
39. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27.
40. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813-2820.